Lymphoma, T-Cell, Peripheral

"Lymphoma, T-Cell, Peripheral" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.

Descriptor ID	D016411
MeSH Number(s)	C04.557.386.480.750.825 C15.604.515.569.480.750.825 C20.683.515.761.480.750.825
Concept/Terms	Lymphoma, T-Cell, Peripheral Lymphoma, T-Cell, Peripheral T-Cell Lymphoma, Peripheral T Cell Lymphoma, Peripheral Lymphoma, T Cell, Peripheral Peripheral T-Cell Lymphoma Lymphoma, Peripheral T-Cell Lymphomas, Peripheral T-Cell Peripheral T Cell Lymphoma Peripheral T-Cell Lymphomas T-Cell Lymphomas, Peripheral

Below are MeSH descriptors whose meaning is more general than "Lymphoma, T-Cell, Peripheral".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Lymphoma [C04.557.386]
Lymphoma, Non-Hodgkin [C04.557.386.480]
Lymphoma, T-Cell [C04.557.386.480.750]
Lymphoma, T-Cell, Peripheral [C04.557.386.480.750.825]
Hemic and Lymphatic Diseases [C15]
Lymphatic Diseases [C15.604]
Lymphoproliferative Disorders [C15.604.515]
Lymphoma [C15.604.515.569]
Lymphoma, Non-Hodgkin [C15.604.515.569.480]
Lymphoma, T-Cell [C15.604.515.569.480.750]
Lymphoma, T-Cell, Peripheral [C15.604.515.569.480.750.825]
Immune System Diseases [C20]
Immunoproliferative Disorders [C20.683]
Lymphoproliferative Disorders [C20.683.515]
Lymphoma [C20.683.515.761]
Lymphoma, Non-Hodgkin [C20.683.515.761.480]
Lymphoma, T-Cell [C20.683.515.761.480.750]
Lymphoma, T-Cell, Peripheral [C20.683.515.761.480.750.825]

Below are MeSH descriptors whose meaning is related to "Lymphoma, T-Cell, Peripheral".

Below are MeSH descriptors whose meaning is more specific than "Lymphoma, T-Cell, Peripheral".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Lymphoma, T-Cell, Peripheral" by people in this website by year, and whether "Lymphoma, T-Cell, Peripheral" was a major or minor topic of these publications.

Bar chart showing 9 publications over 6 distinct years, with a maximum of 2 publications in 2010 and 2011 and 2019

To see the data from this visualization as text, click here.

Year	Major Topic	Total
2007	1	1
2010	2	2
2011	2	2
2012	1	1
2017	1	1
2019	2	2

Below are the most recent publications written about "Lymphoma, T-Cell, Peripheral" by people in Profiles.

Goldbach AR, Hava S, Malik A, Pascarella S. Bilateral breast adenopathy-A rare presentation of peripheral T-cell lymphoma. Breast J. 2019 07; 25(4):735-736.

View in: PubMed
Barta SK, Zain J, MacFarlane AW, Smith SM, Ruan J, Fung HC, Tan CR, Yang Y, Alpaugh RK, Dulaimi E, Ross EA, Campbell KS, Khan N, Siddharta R, Fowler NH, Fisher RI, Oki Y. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):356-364.e3.

View in: PubMed
Haverkos BM, Huang Y, Gru A, Pancholi P, Freud AG, Mishra A, Ruppert AS, Baiocchi RA, Porcu P. Frequency and clinical correlates of elevated plasma Epstein-Barr virus DNA at diagnosis in peripheral T-cell lymphomas. Int J Cancer. 2017 04 15; 140(8):1899-1906.

View in: PubMed
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012 Feb 20; 30(6):631-6.

View in: PubMed
Morgensztern D, Walker GR, Koniaris LG, Lossos IS. Lack of survival improvement in patients with peripheral T-cell lymphoma: a Surveillance, Epidemiology, and End Results analysis. Leuk Lymphoma. 2011 Feb; 52(2):194-204.

View in: PubMed
O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, Lechowicz MJ, Savage KJ, Shustov AR, Gisselbrecht C, Jacobsen E, Zinzani PL, Furman R, Goy A, Haioun C, Crump M, Zain JM, Hsi E, Boyd A, Horwitz S. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011 Mar 20; 29(9):1182-9.

View in: PubMed
Perini G, Pro B. Hepatosplenic gamma-delta T-cell lymphoma, disseminated intravascular coagulation, and systemic mastocytosis: an unusual presentation for a rare disease. Clin Adv Hematol Oncol. 2010 Oct; 8(10):693-4.

View in: PubMed
Pro B, Perini G. Central nervous system prophylaxis in peripheral T-cell lymphoma. Blood. 2010 Jul 1; 115(26):5427.

View in: PubMed
Czuczman MS, Porcu P, Johnson J, Niedzwiecki D, Kelly M, Hsi ED, Cook JR, Canellos G, Cheson BD. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leuk Lymphoma. 2007 Jan; 48(1):97-103.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement